Solve GNE and Genosera Sign Agreement to Develop a Novel Bicistronic AAV Gene Therapy Targeting HIBM
14 août 2023 09h00 HE
|
Solve GNE LLC
LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Solve GNE announced today that it has entered into a sponsored research agreement with Genosera to provide funding for a novel Adeno-Associated Virus...
EHang to Report Second Quarter 2023 Unaudited Financial Results on Thursday, August 17, 2023
11 août 2023 08h25 HE
|
EHang Holdings Limited
GUANGZHOU, China, Aug. 11, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang and Shenzhen Bao’an District Form Strategic Partnership for Urban Air Mobility Operation Center
13 juil. 2023 08h32 HE
|
EHang Holdings Limited
GUANGZHOU, China, July 13, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang Announces US$23 Million Private Placement Led by South Korean Strategic Investor Lee Soo Man
11 juil. 2023 16h00 HE
|
EHang Holdings Limited
GUANGZHOU, China, July 12, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease
01 juin 2023 05h09 HE
|
Rentschler Biopharma SE
Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UKIkarovec is developing novel gene therapies to treat...
Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
31 mai 2023 06h00 HE
|
Coave Therapeutics
CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile Positive results from the study to date support preparations for a...
EHang Reports First Quarter 2023 Unaudited Financial Results
31 mai 2023 05h00 HE
|
EHang Holdings Limited
- Total Revenues Up 41.6% Quarter-over-Quarter- Continued High Quarterly Gross Margin of 60%+- EH216-S Type Certification’s Compliance Tests in Final Phase Completed More Than 90%- Notable Growth of...
Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction
17 mai 2023 07h00 HE
|
Sania Therapeutics
Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction Sania emerges from stealth mode and presents key proof-of-concept data at ASGCT 2023 ...
Coave Therapeutics to Participate in Upcoming Conferences
17 mai 2023 03h00 HE
|
Coave Therapeutics
Paris, France, May 17, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases,...
Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
16 mai 2023 06h00 HE
|
Locanabio, Inc.
LBIO-115 demonstrates robust exon 51 skipping resulting in high levels of dystrophin restoration in patient-derived muscle cells and an in vivo DMD disease model Cas13d Multi-targeting efficiently...